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Abstract
Background: The natural history of acute myocarditis (AM) remains highly variable and predictors of outcome are
largely unknown. The objectives were to determine the potential value of various cardiovascular magnetic
resonance (CMR) parameters for the prediction of adverse long-term outcome in patients presenting with
suspected AM.
Methods: In a single-centre longitudinal prospective study, 203 routine consecutive patients with an initial
CMR-based diagnosis of AM (typical Late Gadolinium Enhancement, LGE) were followed over a mean period of
18.9 ± 8.2 months. Various CMR parameters were evaluated as potential predictors of outcome. The primary
endpoint was defined as the occurrence of at least one of the combined Major Adverse Clinical Events (MACE)
(cardiac death or aborted sudden cardiac death, cardiac transplantation, sustained documented ventricular
tachycardia, heart failure, recurrence of acute myocarditis, and the need for hospitalization for cardiac causes).
Results: The vast majority of patients (N = 143,70 %) presented with chest pain, mild to moderate troponin
elevation and ST-segment or T wave abnormalities. Various CMR parameters were evaluated on initial CMR
performed 3 ± 2 days after acute clinical presentation (LV functional parameters, presence/extent of edema on T2
CMR, and extent of late gadolinium enhancement lesions). Out of the 203 patients, 22 experienced at least one
major cardiovascular event (10.8 %) during follow-up for a total of 31 major cardiovascular events. Among all CMR
parameters, the only independent CMR predictor of adverse clinical outcome by multivariate analysis was an initial
alteration of LVEF (p = 0.04).
Conclusions: In routine consecutive patients without severe hemodynamic compromise and a CMR-based
diagnosis of AM, various CMR parameters such as the presence and extent of myocardial edema and the extent of
late gadolinium-enhanced LV myocardial lesions were not predictive of outcome. The only independent CMR
predictor of adverse clinical outcome was an initial alteration of LVEF.
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Background
Acute myocarditis (AM), which is most frequently
caused by a viral infection [1, 2], is characterized by het-
erogeneous clinical manifestation, including chest pain,
heart failure, arrhythmias, or a combination of these. Al-
though it has been recognized in pathologic studies to
be associated with 8.6 to 12 % of sudden cardiac deaths
[3, 4], and up to 9 % of dilated cardiomyopathy [1, 5, 6],
its clinical presentation is less severe in the vast majority
of the cases and heart failure is uncommon. [7–9] Be-
cause the natural history of AM remains highly variable,
the prognostic stratification is of critical importance.
Endomyocardial biopsy (EMB) remains the gold stand-
ard for the diagnosis of AM but is recommended for the
most severe patients, namely those with acute dilated
cardiomyopathy and hemodynamic compromise, life-
threatening arrhythmias, or those requiring circulatory
support, thus excluding the vast majority of patients pre-
senting with AM in routine practice [10]. EMB is an in-
vasive procedure that may be hampered by a relatively
low sensitivity, because of the focal nature of the disease
[6, 11]. Also, it is limited by interobserver variability and
lacks prognostic value [6, 12]. Cardiovascular Magnetic
Resonance (CMR) has emerged as the most important
non-invasive imaging technique for the diagnosis of AM
[13]. Besides the assessment of functional parameters
such as left ventricular (LV) function and volumes, it
provides comprehensive analysis of myocardial inflamma-
tory process and accurate depiction of various patterns of
irreversible myocardial damage with unprecedented diag-
nostic value [13, 14]. At the acute stage of AM, several
predictors of outcome have been postulated such as ven-
tricular dysfunction [7, 9], advanced New York Heart
Association class [15, 16], elevated pulmonary artery pres-
sure [16], prolonged QRS duration [17], specific histo-
pathological forms or patterns of tissue damage [18, 19],
increased myocardial early gadolinium enhancement ratio
[20], or presence of late gadolinium enhancement [21].
However, these predictors are still controversial [1, 9], and
in particular those extracted from CMR. The aim of this
study was to investigate the potential value of various
CMR parameters for the prediction of adverse long-term




Between October 2008 and December 2011, we con-
ducted a single-centre longitudinal prospective non-
randomized study in consecutive patients presenting
with a first episode of suspected AM at our Institutions
(CMR Laboratory in a tertiary Cardiovascular Centre).
To participate at the screening phase, patients were eli-
gible if they had a clinical presentation suggesting the
diagnosis of AM. Patients who had hat least 3 of the fol-
lowing criteria: 1) chest pain, 2) recent history (<1 month)
of acute viral infection, 3) abnormal ST segment or T
waves on ECG, 4) troponin elevation, were eligible to
undergo CMR at the time of acute clinical presentation.
Patients presenting with ST segment elevation >1 mm in at
least 2 contiguous derivations were scheduled for prompt
coronary angiography. They were eligible for the CMR
study if the coronary angiogram did not show any signifi-
cant (>50 % diameter stenosis) coronary disease. Patients
were then eligible to participate in the study if initial CMR
showed nonischemic suggestive patterns of AM as defined
below and if the patient had no contraindication to CMR.
Exclusion criteria were: 1) severe noncardiac disease
compromising life expectancy during the period of the
study 2) pre-existing other cardiac disease, 3) relevant
coronary artery disease (coronary stenosis ≥50 %) proven
by angiography, 4) severe hemodynamic compromise
that precluded the CMR study. All patients gave in-
formed written consent and the study was approved by
the Local Ethic Committee of our Institutions.
Study protocol
The patients eligible for participation in the study were
scheduled to undergo CMR at our Institutions between
day 0 and day 7 after initial presentation with a detailed
CMR protocol as described below. When the diagnosis
of AM was made on CMR, medical treatment included
ASA (3 g per day), β-blockers and ACE inhibitors for at
least 6 weeks. Supporting therapy was provided when
appropriate in case of acute or subacute heart failure.
Patients with diagnosis of AM were then included after
informed consent and scheduled for a follow up assess-
ment between 12 and 18 months after the initial event.
The follow up consisted of a clinical visit for patients
who were initially hospitalized in our Institutions or a
direct contact with the patient and the referring cardi-
ologist for patients who were initially referred to our
CMR suite from other hospitals. For all patients, a clin-
ical questionnaire with a detailed description of clinical
study endpoints was thoroughly filled out by two senior
cardiologists (FS, JG) in charge of the follow up assess-
ment. The LV function was assessed by CMR when
available or by echocardiography between 6 months and
one year after initial presentation.
Study end-points
Patients were followed over time and the primary clinical
end-point was the occurrence of at least one of the com-
bined Major Adverse Clinical Events (MACE) defined by:
cardiac death (or aborted sudden cardiac death), cardiac
transplantation, sustained documented ventricular tachy-
cardia (documented by Holter ECG or ECG in symptom-
atic patients), the need for hospitalization for heart failure
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(NYHA class IV and III), recurrence of acute myocarditis,
and the need for hospitalization for cardiac causes. Clin-
ical event adjudication was based on the follow up clinical
visit or contact, with a consensus reached by the 2 senior
cardiologists in charge of follow up (FS, JG). The second-
ary end-points were the LV ejection fraction (EF) on last
echocardiography (by Simpson’s biplane analysis) or on
CMR (the intra-individual comparisons were made by the
same method), and the persistence of clinical symptoms
as defined by a clinical score as follows: 1 point for chest
pain, palpitations, arrhythmia, asthenia; 1 point for each
NYHA functional class; 1 point for the need of a referral
to the cardiologist; and 3 points for hospitalization.
CMR acquisitions
In eligible patients, CMR was promptly performed be-
tween day 0 and day 7 after acute clinical presentation in
a dedicated Cardiovascular MR laboratory on a Siemens
Magnetom Espree® 1,5 T scanner (Erlangen, Germany)
with 32-channel anterior and spinal coils for reception.
Long-axis (2-, 3-, and 4-chamber) and short-axis cine MR
images encompassing the left ventricle from base to apex
were obtained with a retrospectively gated fast imaging
Steady State Free Precession (SSFP) sequence. Myocardial
edema and inflammation was investigated in matched
long axis 2-, 3-, and 4—chamber, and in short-axis views
through T2-weigthed triple inversion-recovery turbo spins
echo sequence with inversion pulses for fat and blood
suppression. Then, a bolus of gadolinium contrast
(Dotarem®, Guerbet, Aulnay, France, 0.1 mmol/kg) was
injected at a rate of 4 ml/s with an injector (Optistar Elite
Mallinckrodt). Focal early gadolinium enhancement (EGE)
was visually assessed on SSFP cine-MR images in the long
axis 2-, 3-, 4-chamber views and short-axis locations, ac-
quired between 2 and 5 min. after Gadolinium injection.
Late gadolinium enhanced (LGE)-CMR was acquired
10 min. after contrast administration in matched long axis
2-, 3-, 4- chamber and short-axis views through the use of
spoiled 2D fast gradient echo inversion-recovery sequence
with a TI set to null normal myocardial signal (TI scout
sequence). The diagnosis of AM was made based on the
following criteria: 1) spontaneous intramyocardial and/or
supepicardial hypersignal on T2-weighted spin echo im-
ages indicative of myocardial edema, 2) intramyocardial
and/or supepicardial LGE on CMR images, 3), absence of
microvascular obstruction and acute myocardial infarc-
tion (MI) on CMR images. The criteria 2 and 3 were
mandatory for the diagnosis of AM and participation to
the study.
When the diagnosis of AM was made, medical treat-
ment included ASA (3 g per day), β-blockers and ACE
inhibitors for at least 6 weeks. Supporting therapy was
provided when appropriate in case of acute or subacute
heart failure.
CMR analysis
CMR images were analyzed by two blinded experienced
observers and in case of discordance by a third observer
for consensus. Myocardial segmentation was assessed
using the 17-segment model according to the consensus
of the North American Society of Myocardial Imaging.
Endocardial and epicardial borders were manually traced
on end-diastolic and end-systolic short-axis cine images
from base to apex. LV volumes and ejection fraction
were derived by summation of epicardial and endocar-
dial contours (Argus® Software, Siemens, Erlangen,
Germany). Myocardial edema was assessed as a hyper-
signal that was present before contrast injection on
black-blood T2-weighted images. The extent of myocar-
dial edema on T2-weighted images, of early gadolinium
enhancement (EGE) on cine images and of late gadolin-
ium enhancement (LGE) was assessed through the use
of a semi-quantitative analysis. Each of the 17 LV myo-
cardial segments was divided into 3 layers (outer, mid
and inner). The presence of myocardial lesions was de-
termined in each of the 3 layers for each myocardial seg-
ment. Finally, myocardial lesions on CMR data were
delineated by planimetry using an automated threshold
greater than 4SD above mean myocardial signal intensity
and expressed as percentage of LV myocardial surface
area. Myocardial damage on LGE-CMR was localized in
details in the sub-epicardium, midwall or transmural
and its shape was characterized as nodular or linear.
Statistical analysis
Statistical analysis was performed using STATA 10.1
(Statacorp LP, Texas USA). Baseline descriptive statistics
are presented as frequency and percentage for categorical
variables and mean ± SD or median (interquartile range)
for continuous variables. The normality of data was
assessed using the Skewness and Kurtosis normality test.
The differences between the groups were assessed with the
chi-square test or Fisher exact test for categorical data and
Student t-test for continuous data. Differences between
groups were considered statistically significant if the 95 %
CI around the difference of the means did not contain zero.
In a prespecified analysis, baseline predictors for MACE
were identified using Cox multivariate analysis including
variables showing a p value <0.20 in association with
MACE by univariate analysis. In the multivariate analysis,
colinearity was considered if Pearson’s correlation coeffi-
cient was > 0.6 or the standard error of a covariate was >
5.0. If colinearity was identified, the multivariate analysis
was repeated after removal of the responsible covariate.
Results
Study population
Overall, 240 patients were screened to participate. Six of
them had contra-indications to MRI (claustrophobia in
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4, metallic ocular implants in 1, cerebral aneurysm clip in
1) and only one refused to participate. Thus, 233 patients
were considered for the study. Out of them, 28 patients
were excluded because of the presence of relevant coronary
artery disease in 8, severe hemodynamic compromise in 3
(cardiogenic shock), myocardial involvement in inflamma-
tory systemic diseases in 5 (including sarcoidosis, Behcet,
Churg Strauss, Lyme disease or sepsis), other concomitant
cardiac diseases in 9 (chemotherapy-induced cardiomyop-
athy, valve disease, arrhythmogenic right ventricular dys-
plasia), and pericardial diseases in 3. Finally, 205 patients
were enrolled in the study and followed over time. Two pa-
tients were lost to follow-up and the final study population
consisted of 203 patients. The baseline characteristics of
patients are detailed in Table 1. The vast majority of pa-
tients (N = 143, 70 %) presented with a clinical scenario in-
cluding chest pain, mild to moderate troponin elevation
and ST-segment or T wave abnormalities on ECG. Out of
these 143 acute coronary syndrome-like patients, 99 (69 %)
had prompt normal coronary angiography because of ST
segment elevation in at least 2 contiguous derivations. In
the 44 remaining patients (31 %), coronary angiography
was not performed because of the lack of ST segment ele-
vation and a very low risk profile (mean age 40 years, no
cardiovascular risk factors). The remaining 60 patients
had a presentation that included for the majority of
them a clear recent history of acute viral infection with
fever (38/60), and the characteristics of chest pain were
highly suggestive of non ischemic origin (variable with
respiratory motion, relieved by aspirin). Ten patients
presented with mild or moderate heart failure, 12 with
arrhythmias. All patients were relatively young and had
no cardiovascular risk factors. They all had typical pat-
terns of acute non ischemic lesions on LGE-CMR (mul-
tiple, nodular, subepicardial) and for those reasons were
not referred to cath. The other symptoms at initial
presentation are listed in Table 1. The clinical score at
presentation was 4.6 ± 1.5.
CMR data
The initial CMR findings are listed in Table 2. CMR was
performed in all patients at a mean of 3 ± 2 days after
acute clinical presentation. Mean LVEF was 57 % and
mean end-diastolic LV volume was 73 ml/m2. Out of the
203 patients, 39 (19 %) presented at least one asynergic
myocardial segment on cine CMR. Hyper-T2 myocardial
signal on fat suppressed black-blood spin echo T2-
weighted CMR was present in 100 patients (62.5 %) with
a mean extent of 10.9 ± 5.7 % of LV myocardial mass.
Myocardial lesions on LGE were mostly limited in the
posterolateral LV wall (60 %), often nodular (74 %), and
located in the sub-epicardial layers (82 %) with a mean
Table 1 Baseline characteristics of study patients
N (203)
Age, yrs 42.7 ± 16.5
Male (N,%) 155 (76)
History of cardiovascular disease (N,%) 4 (2)
Time between symptoms onset and CMR (days) 3 ± 2
Time between CMR and subsequent
assessment of LV EF (months)
9.8 ± 6.8
Time between CMR and follow-up (months) 18.9 ± 8.2
Initial clinical score 4.6 ± 1.5
Clinical presentation at acute stage (N,%)
Chest pain - ST and/or T ECG
changes - elevated troponin
143 (70)
Chest pain – recent history of viral
infection – elevated troponin
22(11)
Chest pain – recent history of viral
infection – ST and/or T ECG changes
16(8)
Sustained ventricular arrhythmias, cardiac arrest 12 (6)
Heart failure 10 (5)
Data are expressed as mean ± SD unless specified
Table 2 Initial findings on CMR
LVEF at diagnosis, % 57.0 ± 9.0
LVEDV at diagnosis, ml/m2 72.9 ± 18.0
Patients with pericardial effusion (N,%) 58 (28.4)
Patients with asynergic myocardial segments (N,%) 39 (19)
LGE
Number of patients with LGE (N,%) 203 (100)
Number of segments with LGE, N 3.8 ± 2.2
Myocardial extent of LGE (% myocardial surface area) 11.4 ± 7.0
Nodular Pattern (N,%) 150 (73.5)
Sub-epicardial lesions (N,%) 168 (82.3)
Midwall lesions (N,%) 33 (16.1)
Transmural lesions (N,%) 2 (1.0)
Presence of LGE in opposed walls (N,%) 77 (38.0)
Postero-lateral localization (N,%) 122 (60)
Anterior wall involved (N,%) 17 (8.3)
Postero-lateral and septal localisation (N,%) 60 (29.4)
Hyper T2 signal
Number of patients with hyper T2 (N,%) 100 (62.5)
Number of segments with hyper T2 signal 1.9 ± 1.8
Myocardial extent of Hyper T2 (% myocardial surface area) 10.9 ± 5.7
Presence of T2 hyper-signal in opposed walls (N,%) 34 (21.2)
EGE
Number of patients with EGE (N,%) 114 (56)
Number of segments with EGE 1.8 ± 1.9
Myocardial extent of EGE (% myocardial surface area) 8.6 ± 5.4
Presence of local EGE in opposed walls (N,%) 30 (14.7)
Values are expressed as mean ± SD unless specified
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myocardial extent by planimetry of 11.4 ± 7.0 % of LV
myocardial mass.
Follow-up data
The clinical follow-up was assessed after a mean period
of 18.9 ± 8.2 months. Out of the 203 patients, 22 experi-
enced at least one major cardiovascular event (10.8 %)
during follow-up. A total of 31 major cardiovascular
events occurred during the study period and their char-
acteristics are detailed in Table 3. LVEF at follow-up was
greater than 50 % in 88.7 % of patients. Mean clinical
score at follow-up was 0.6 ± 1.1, and 57 patients (28 %)
had a clinical score >1 at follow-up.
CMR predictors of outcome
Primary endpoints
By univariate analysis, the presence and extent of early
gadolinium enhancement were inversely related to the
occurrence of MACE (mean number of myocardial seg-
ments exhibiting EGE 1.9 ± 1.9 in patients without
MACE vs. 1.0 ± 1.7 in patients with MACE, p = 0.04; and
mean myocardial extent of EGE 5.1 ± 6.0 % of LV myo-
cardial mass vs. 2.2 ± 4.1 %, respectively, p = 0.0056)
(Table 4). Although not significant, the extent of T2 le-
sions on initial black-blood T2-weighted CMR was also
greater in patients without MACE relative to patients
with subsequent MACE (7.0 ± 7.0 % vs. 4.9 ± 4.9 % of LV
mass, respectively, p = 0.16) (Figs. 1 and 2). A lower ini-
tial LVEF was associated with adverse clinical outcome
(57.6 ± 8.9 % in patient without MACE vs. 51.9 ± 9.0 %
in patients with MACE, p = 0.009). No relationship was
found between the extension, patterns (nodular/linear),
localisation and wall distribution of LGE lesions and the
occurrence of MACE (Figs. 1 and 2). By multivariate
analysis, the only independent CMR predictor of adverse
clinical outcome at follow-up was an initial alteration of
LVEF (Table 5).
Secondary endpoints
There was an inverse association between the extent of
T2 lesions and the persistence or occurrence of clinical
symptoms during follow-up (mean extent of T2 lesions
7.5 ± 7.4 % of LV mass in asymptomatic vs. 4.8 ± 5.1 % in
symptomatic patients, p = 0.01). Also, an initial alteration
of LVEF was associated to the presence of clinical symp-
toms at follow-up (55.0 ± 8.2 % in patients presenting
symptoms at follow-up vs. 57.8 ± 9.3 % in asymptomatic,
p = 0.04). Initial alteration of LVEF at diagnosis was
found to be significantly associated to an abnormal EF at
follow-up (patients with LVEF < 50 % at follow-up had an
initial LVEF of 47.0 ± 10.7 %, vs. an initial LVEF of 57.3 ±
9.0 % in patients with follow-up LVEF ≥50 %; p = 0.001). A
larger LV end-diastolic volume at initial presentation was
associated to altered LVEF at follow-up (85.9 ± 21.7 ml/m2
in patients with altered follow-up LVEF vs. 71.8 ± 17.1 ml/
m2 in those with preserved LVEF, p = 0.02). No relation-
ship was found between the extension, patterns (nodular/
linear), localisation and wall distribution of LGE lesions
and subsequent alterations of LV functional parameters.
Similarly, no association was found between the extent of
EGE or T2 lesions and LVEF (P =NS).
Discussion
In this prospective series of 203 consecutive patients pre-
senting with a CMR-based diagnosis of AM, the initial
CMR data including the presence and extent of acute focal
myocardial edema and the extent of myocardial tissue
damage on LGE-CMR were not independently related to
clinical outcome. By multivariate analysis, the only inde-
pendent predictor of outcome on CMR was the alteration
of LV ejection fraction at the initial CMR performed early
after the onset of AM.
The current data highlight the value of global LV sys-
tolic function as an independent predictor of outcome in
AM and are in good agreement with that from Caforio
et al. who reported that biventricular dysfunction at
diagnosis was the main predictor of death/transplant-
ation in patients with myocarditis [7]. Accordingly,
Anzini et al. showed that baseline LV function was a
marker for prognosis in a series of 82 patients with AM
regardless of the clinical pattern of disease onset [9]. Be-
cause only a small number of patients underwent CMR
in this study, potential CMR predictors could not be
evaluated. The current study provides a prospective ana-
lysis of CMR predictors of long term outcome in a rela-
tively large population of consecutive patients with
suspected AM. To participate in the study, patients had
to undergo CMR at the acute phase of AM, leading to
the exclusion of the most severe, in particular those with
hemodynamic compromise. However, this resulted in
the exclusion of only 3 patients during the study period.
Therefore, it should be emphasized that the main find-
ings of the present study are valid in a population of pa-
tients with CMR-based diagnosis of AM in absence of
severe heart failure, which is by far the most frequent
presentation in clinical practice. In addition, it has been
shown that fulminant myocarditis is a distinct clinical
entity with an excellent long-term prognosis in patients
Table 3 Mayor Adverse Clinical Events (MACE) at follow-up
Number of patients with MACE (N,%) 22 (10.8 %)
Hospitalization for cardiac causes 8
Heart failure 4
Ventricular Tachycardia 8
Recurrence of myocarditis 11
Cardiac transplantation or Death or
Aborted sudden cardiac death
0
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who survive after the acute phase of AM [22]. Therefore,
the determination of long term predictors of outcome in
those patients may be less needed. The characteristics of
our study population may account for the apparent con-
flicting results reported by Grün et al., where the authors
studied a cohort of 203 patients with biopsy-proven
myocarditis and found that the presence of LGE was an
independent predictor of long-term all-cause mortality
and cardiac mortality [21]. It is important to point out
that the characteristics of the study population were
quite different, since a significant proportion of patients
presented with heart failure (almost 45 % of patients
presenting with an advanced NYHA class III or IV, and
more than 76 % presenting with NYHA II-III or IV
Class) and altered LV functional parameters (mean LVEF
of 45 %). It has been shown that viral genomes are fre-
quently detected in EMBs of patients with systolic LV
dysfunction and that myocardial persistence of various
viruses, often presenting as multiple infections, may play
a role in the transition from myocarditis to dilated car-
diomyopathy [23], or as a precipitating factor for heart
failure [15]. Also, patients of the current sudy were in-
cluded on the basis of a LGE positive CMR and there-
fore the presence of LGE per se could not be evaluated
Table 4 Univariate analysis for CMR predictors of Major Adverse Cardiac Events
Variables Presence of MACE at
FU (N = 22)
Absence of MACE at
FU (N = 181)
P value OR
(95 % CI)
CMR Pattern P = 0.094 2.16 (0.86–5.38)
Nodular 13 137
Linear 9 44








Septal + posterolateral 6 54
Presence of pericardial effusion 9 49 P = 0.18 1.86 (0.75–4.64)
Gender P = 0.87
Male 137 17
Female 44 5
Presence and extent of Early Gadolinium Enhancement
(% myocardial surface area)
2.2 % ± 4.1 5.1 % ± 6.0 P = 0.005
Number of segments with EGE 1.0 ± 1.7 1.9 ± 1.9 P = 0.04
Age 47 ± 13 42 ± 17 P = 0.14 0.91 (0.32–2.62)
Presence of asynergic segments on CMR 6 33 P = 0.31 1.68 (0.61–4.62)
Presence of EGE in 2 opposed walls 3 27 P = 0.87 0.90 (0.25–3.25)
Presence of LGE in 2 opposed walls 8 69 P = 0.87 0.93 (0.37–2.32)
Myocardial extent of Late Gadolinium Enhancement
(% myocardial surface area)
11.9 % ± 6.8 11.3 % ± 7.2 P = 0.72
Number of segments with LGE 4.2 ± 2.4 3.7 ± 2.2 P = 0.41
Presence of T2-hypersignal 8 92 P = 0.69 0.81 (0.27–2.46)
Presence of T2-hypersignal in opposed walls 2 32 P = 0.50 0.59 (0.13–2.79)
Myocardial extent of hyper T2 signal
(% myocardial surface area)
4.9 ± 4.9 7.0 ± 7.0 P = 0.16
Number of segments with hyper T2 signal 1.9 ± 1.8 1.9 ± 1.9 P = 0.9
Initial end-diastolic LV volume, ml/m2 77 ± 22 73 ± 18 P = 0.39
Initial LV ejection fraction, % 51.9 ± 9 57.6 ± 8.9 P = 0.009
Data are presented as mean value, ± Standard Deviation
Sanguineti et al. Journal of Cardiovascular Magnetic Resonance  (2015) 17:78 Page 6 of 9
as a potential predictor of outcome. As previously men-
tioned, the presence/extent of myocardial edema and
EGE, as well as the extent of LGE and parameters of LV
function, were assessed.
In the current study, the diagnosis of acute myocardi-
tis was based on the acute clinical presentation (mostly
acute chest pain) with electrocardiographic and/or bio-
logical data, and CMR that showed nodular or linear
intra-myocardial lesions highly suggestive of acute non-
ischemic tissue damage. The criteria for the diagnosis of
AM on CMR were slightly different from the established
Lake-Louise criteria where AM is present when 2 out of
3 parameters (increased signal on T2, early enhancement
and late-enhancement) are met [13]. In our study,
lesions of LGE had to be present with typical patterns of
AM because this parameter is more specific and could
limit the inclusion of patients with myocardial edema of
other causes. For the same reason, we did not include
patients with clinically suspected acute myocarditis but
negative CMR because we believe that the diagnosis
often remains uncertain in those cases and this might
have led to an inhomogeneous group of patients. The
diagnosis of AM was not proven by biopsy in agreement
with practice Guidelines, since only 5 % of the patients
presented with mild to moderate heart failure and
responded to conventional medical therapy [10]. Patients
Fig. 1 CMR data of a 25 year-old male performed at day 1 after the
onset of an acute coronary-like syndrome (chest pain, ST segment
alterations, mild troponin elevation). Black blood T2-weighted STIR
CMR indicates the presence of segmental diffuse myocardial edema
of the LV posterior and lateral walls representing 23 % of LV mass
(top panel, arrows). Late gadolinium-enhanced CMR shows diffuse
subepicardial nodular lesions in the posterolateral and lateral walls
of the LV (11 % of LV mass) indicative of acute myocarditis (mid
panel, arrows). Cine-MR at day 1 and 6 months (bottom panel)
showed normal systolic global and segmental LV function
(LV end-diastolic volume index 71 ml/m2, LV ejection fraction 61 %;
69 ml/m2 and 63 %, respectively). The patient did well and had no
MACE during follow-up
Fig. 2 CMR data findings of a 56-year-old male performed at day 2
after the onset of an acute coronary-like syndrome (chest pain, ST
segment alterations, mild troponin elevation). Black blood T2-
weighted STIR CMR indicates the presence of limited subepicardial
hypersignal in the mid portion of the posterolateral and lateral LV
walls, indicative of small foci of myocardial edema (top panel,
arrows, 4 % LV mass). Late gadolinium-enhanced CMR shows limited
subepicardial nodular lesions in the mid portion of the posterolateral
and lateral LV walls (mid panel, arrows, 6 % LV mass), indicative of
acute myocarditis. Cine-MR at day 2 and 6 months (bottom panel)
showed altered systolic global LV function (LV end-diastolic volume
index 83 ml/m2, LV ejection fraction 45 %; 101 ml/m2 and 36 %,
respectively). Despite optimal medical therapy, the patient suffered
NYHA Class III heart failure during follow-up with diffuse LV
hypokinesia predominant in the lateral wall
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with hemodynamic compromise were not included and
the study confirms that acute myocarditis has an excel-
lent prognosis in routine consecutive patients [1, 2]. It
should also be emphasized that the presence of a typical
pattern of LGE on initial CMR was an inclusion criter-
ion, therefore the presence/absence of LGE could not be
evaluated as a potential predictor of outcome.
Although not significant, there was a clear trend be-
tween the presence and extent of myocardial edema on
initial T2-weighted CMR and a lower rate of subsequent
MACE, as well as less persistent clinical symptoms during
follow-up. Recently, McLellan et al. reported concordant
results in patients with acute onset cardiomyopathy,
showing that the amount of myocardial inflammation
identified by an elevated global relative enhancement
(GRE) could predict recovery of LV function [20]. How-
ever, the acquisition sequences for depiction of myocardial
edema were different in those 2 single-centre studies, and
other studies will be needed to confirm or infirm this find-
ing. The lesions of EGE were not assessed by the EGE ra-
tio (EGEr) with normalization to the signal of the skeletal
muscle, but with the use of a threshold of 4 SD above the
mean signal of remote myocardium [13]. In the 2009
JACC white paper, it is stated that the EGE may be visually
appreciated and that there is no demonstration of the
diagnostic superiority of EGEr over the visual assessment
for the diagnosis of AM [13]. Also, the patients enrolled in
the study were non severe patients and the probability to
have diffuse and homogeneous inflammation of the myo-
cardium was weak.
Overall, the current study confirms and highlights the
favorable outcome of patients presenting with initially
non severe AM and no hemodynamic compromise. For
this reason, the combined clinical primary end point was
broad and no patient experienced a hard event (trans-
plantation, cardiac death or aborted cardiac death). Re-
cently, Schumm et al. reported that patients presenting
with suspected clinical myocarditis and normal CMR
scans had favorable outcomes [24].
In our sudy population, the lower extent of EGE as
compared to LGE might appear to be in contradiction to
the sole physiology of gadolinium kinetics within the
myocardium. As stated in the White JACC paper, T2 se-
quences for depiction of regional edema may have a
limited sensitivity in less severe inflammation [13]. It is
likely that in the studied homogeneous population of pa-
tients presenting with unsevere acute myocarditis and
no hemodynamic compromise (by far the most frequent
patients presenting with AM), the lack of sensitivity of
conventional sequences (either T2-STIR or SSFP cines)
in such unsevere AM, as the lack of contrast at least for
SSFP, may account for the lower extent of lesions in
such sequences as compared to LGE, which by basics
principles is set to optimize contrast.
Finally, an ischemic etiology was ruled out in a signifi-
cant proportion of patients based upon clinical param-
eter assumption and CMR characteristics. This is a
limitation of the study since no specific examination was
performed to formally rule out coronary disease. The
study did not provide comparisons between biomarkers
and myocardial lesions on CMR in relation to the clin-
ical outcome. Also, the empirical medical regimen based
on betablockers and ACE inhibitors might have had
some influence on patient outcomes and this impact is
largely unknown.
Conclusions
In routine consecutive patients without severe hemo-
dynamic compromise and a CMR-based diagnosis of acute
myocarditis, various CMR parameters such as the pres-
ence and extent of myocardial edema and the extent of
late gadolinium-enhanced LV myocardial lesions were not
predictive of outcome. The only independent CMR pre-
dictor of adverse clinical outcome at follow-up was an ini-
tial alteration of LVEF.
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